AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28165812 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bupivacaine and Lipid emulsion (Bup1000LE)
Number of subjects: 0
Study 26063354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate (100 mg three times daily for 6 months)
Number of subjects: 120
Study 26063354 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg once daily for 6 months)
Number of subjects: 120
Study 23242806 — intervention group
Group type: EXPERIMENTAL
Intervention: n-of-1 trial with methylphenidate
Number of subjects: 50
Study 23242806 — intervention group
Group type: COMPARATOR
Intervention: traditional prescription approach
Number of subjects: 50
Study 21770896 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnoea (IH)
Number of subjects: 44
Study 21770896 — intervention group
Group type: COMPARATOR
Intervention: Conventional recovery (C)
Number of subjects: 44
Study 18272842 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration + RAD
Number of subjects: 58
Study 18272842 — intervention group
Group type: COMPARATOR
Intervention: CRRT alone
Number of subjects: 58
Study 16527492 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-laced gelatin
Number of subjects: 0
Study 16527492 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic placebo gelatin
Number of subjects: 0
Study 11772801 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 120
Study 11772801 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 120
Study 10190919 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-neutrophil cytoplasmic antibodies (ANCAs) and anti-Saccharomyces cerevisiae antibodies (ASCA) together
Number of subjects: 120
Study 10190919 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCAs
Number of subjects: 120
Study 10190919 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCA pattern characteristic of UC (perinuclear ANCAs eliminated by DNAse)
Number of subjects: 120
Study 10190919 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer ANCAs
Number of subjects: 120
Study 10190919 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCA
Number of subjects: 120
Study 7497486 — intervention group
Group type: EXPERIMENTAL
Intervention: VasoSeal (collagen vascular hemostasis device)
Number of subjects: 101
Study 7497486 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 101
Study 2301656 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital therapy
Number of subjects: 36
Study 2301656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 36
Study 2301656 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 36
Study 7000296 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 24
Study 7000296 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg once daily
Number of subjects: 24
Study 7000296 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily + Chlorthalidone 25 mg once daily
Number of subjects: 24
Study 7000296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31789564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-detection group
Number of subjects: 145
Study 31789564 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding condition
Number of subjects: 145
Study 31789564 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 145
Study 28379536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (early treatment)
Number of subjects: 871
Study 28379536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (delayed treatment)
Number of subjects: 871
Study 27111644 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-G multiport wire-reinforced catheter
Number of subjects: 46
Study 27111644 — intervention group
Group type: COMPARATOR
Intervention: 19-G uniport wire-reinforced catheter
Number of subjects: 46
Study 27111644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both catheter types
Number of subjects: 46
Study 24618326 — intervention group
Group type: EXPERIMENTAL
Intervention: TSP‐1 rs1478604 A SNP
Number of subjects: 378
Study 24618326 — intervention group
Group type: EXPERIMENTAL
Intervention: ACA haplotype (rs1478604, rs2228261, rs2228262)
Number of subjects: 378
Study 22295895 — intervention group
Group type: EXPERIMENTAL
Intervention: (R,S)‐Ket (0.5 mg kg⁻¹) infusion for 40 min
Number of subjects: 9
Study 19779370 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional and postoperative TENS (Group A)
Number of subjects: 38
Study 19779370 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative TENS only (Group B)
Number of subjects: 38
Study 19779370 — intervention group
Group type: COMPARATOR
Intervention: Sham control (Group C)
Number of subjects: 38
Study 17698683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg/d)
Number of subjects: 8171
Study 17698683 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU every other day)
Number of subjects: 8171
Study 17698683 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (50 mg every other day)
Number of subjects: 8171
Study 17698683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid and Vitamin E (combined)
Number of subjects: 8171
Study 16202900 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied to the groin 60 minutes before the procedure
Number of subjects: 40
Study 16202900 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine infiltrated at the site 5 minutes before the procedure (Control)
Number of subjects: 40
Study 12362933 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 3000 mg
Number of subjects: 23
Study 12362933 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate 2668 mg
Number of subjects: 23
Study 12362933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer HCl 2821 mg
Number of subjects: 23
Study 12362933 — intervention group
Group type: COMPARATOR
Intervention: Iron alone
Number of subjects: 23
Study 12669736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day for 3 years
Number of subjects: 0
Study 12669736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day for 3 years
Number of subjects: 0
Study 12669736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg/day for 2 years followed by 5 mg/day for 1 year
Number of subjects: 0
Study 12669736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7758493 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium salt of penicillin V, 50,000 U/kg per day in three divided doses
Number of subjects: 3
Study 7758493 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine salt of penicillin V, 50,000 U/kg per day in two divided doses
Number of subjects: 3
Study 7758493 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine salt of penicillin V, 100,000 U/kg per day in two divided doses
Number of subjects: 3
Study 7758493 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 3
Study 2265640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 192
Study 2265640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (within 3 hours)
Number of subjects: 192
Study 2265640 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase (3-6 hours after onset)
Number of subjects: 192
Study 7410746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lodoxamide ethyl
Number of subjects: 12
Study 7410746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg lodoxamide ethyl
Number of subjects: 12
Study 7410746 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lodoxamide ethyl
Number of subjects: 12
Study 7410746 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31693081 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRAF-assisted thyroidectomy
Number of subjects: 241
Study 31693081 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroidectomy (control group)
Number of subjects: 241
Study 30569216 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg
Number of subjects: 345
Study 30569216 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg
Number of subjects: 345
Study 30569216 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 345
Study 28333288 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab induction therapy
Number of subjects: 0
Study 26914371 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Dulce technology-enhanced with mobile tools (PD-TE)
Number of subjects: 0
Study 26914371 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Dulce-only (PD)
Number of subjects: 0
Study 26914371 — intervention group
Group type: COMPARATOR
Intervention: IMSS standard of care/control group (CG)
Number of subjects: 0
Study 24581318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular subclavian venous cannulation
Number of subjects: 60
Study 24581318 — intervention group
Group type: COMPARATOR
Intervention: Landmark method
Number of subjects: 60
Study 24581318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 22793965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoprofen 150 mg preemptively administered every 12 hours for two days before surgery
Number of subjects: 13
Study 22793965 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered every 12 hours for two days before surgery
Number of subjects: 13
Study 22793965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoprofen 150 mg administered every 12 hours for three days post-surgery
Number of subjects: 13
Study 19117872 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early surfactant therapy with nasal continuous positive airway pressure
Number of subjects: 279
Study 19117872 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous airway pressure alone
Number of subjects: 279
Study 17126951 — intervention group
Group type: COMPARATOR
Intervention: 6 min infusion of vinorelbine
Number of subjects: 83
Study 17126951 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 min bolus of vinorelbine
Number of subjects: 83
Study 15821618 — intervention group
Group type: EXPERIMENTAL
Intervention: Needlescopic appendectomy (NA)
Number of subjects: 363
Study 15821618 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic appendectomy (CLA)
Number of subjects: 363
Study 12413984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) combined with clomiphene citrate (CC)
Number of subjects: 230
Study 12413984 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with clomiphene citrate (CC)
Number of subjects: 230
Study 9856966 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (20 ng/kg per minute)
Number of subjects: 9
Study 9856966 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study 9856966 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 9
Study 1507329 — intervention group
Group type: EXPERIMENTAL
Intervention: Siemens Lithostar
Number of subjects: 2206
Study 1507329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornier HM4
Number of subjects: 2206
Study 1507329 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Piezolith 2300
Number of subjects: 2206
Study 1507329 — intervention group
Group type: EXPERIMENTAL
Intervention: Direx Tripter X-1
Number of subjects: 2206
Study 1507329 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakstone lithotriptor
Number of subjects: 2206
Study 1507329 — intervention group
Group type: COMPARATOR
Intervention: First generation unmodified Dornier HM3 lithotriptor
Number of subjects: 2206
Study 6089950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 6
Study 6089950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31397579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypidone hydrochloride (YL-0919)
Number of subjects: 0
Study 30028519 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 114
Study 30028519 — intervention group
Group type: COMPARATOR
Intervention: Prednisone/prednisolone
Number of subjects: 114
Study 27119237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib plus lenalidomide-dexamethasone
Number of subjects: 722
Study 27119237 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lenalidomide-dexamethasone
Number of subjects: 722
Study 25128004 — intervention group
Group type: EXPERIMENTAL
Intervention: Relating therapy (16 hours, weekly sessions of one hour)
Number of subjects: 15
Study 25128004 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 15
Study 22897633 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised goal-directed therapy targeting stroke volume and oxygen delivery
Number of subjects: 70
Study 22897633 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 70
Study 20632115 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga
Number of subjects: 102
Study 20632115 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal exercises
Number of subjects: 102
Study 18312661 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and TENS (A&T)
Number of subjects: 32
Study 18312661 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (ACP)
Number of subjects: 32
Study 18312661 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (TENS)
Number of subjects: 32
Study 18312661 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 32
Study 16635606 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin)
Number of subjects: 70
Study 16635606 — intervention group
Group type: COMPARATOR
Intervention: No-statin group
Number of subjects: 70
Study 12569384 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based neoadjuvant chemotherapy
Number of subjects: 97
Study 10960802 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine as a single agent
Number of subjects: 0
Study 10960802 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study 9093230 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive corticosteroid therapy
Number of subjects: 0
Study 9093230 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis
Number of subjects: 0
Study 8334048 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 18
Study 8334048 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 18
Study 2953312 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel applied twice daily
Number of subjects: 40
Study 2953312 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 40
Study 2953312 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel
Number of subjects: 40
Study 2953312 — intervention group
Group type: COMPARATOR
Intervention: Both metronidazole and vehicle
Number of subjects: 40
Study 31201669 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal volunteering for a minimum of 1 hour per week
Number of subjects: 445
Study 31201669 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific intervention, continue life as usual)
Number of subjects: 445
Study 29444376 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (every 4 weeks)
Number of subjects: 168
Study 27938875 — intervention group
Group type: EXPERIMENTAL
Intervention: Abortion stigma perception (ASP)
Number of subjects: 306
Study 27938875 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscarriage stigma perception (MSP)
Number of subjects: 306
Study 27938875 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative stigma perception (CSP)
Number of subjects: 306
Study 24463236 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week resistance training program (RTP) for knee extensors muscles
Number of subjects: 42
Study 24463236 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no specific training
Number of subjects: 42
Study 22708706 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized counseling (Group A)
Number of subjects: 66
Study 22708706 — intervention group
Group type: COMPARATOR
Intervention: Non-standardized counseling (Group B)
Number of subjects: 66
Study 19958076 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone therapy (EPT)
Number of subjects: 20
Study 17503172 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence self-efficacy
Number of subjects: 275
Study 17503172 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 275
Study 17503172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-oriented interventions
Number of subjects: 275
Study 15714241 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic irrigation
Number of subjects: 53
Study 15714241 — intervention group
Group type: COMPARATOR
Intervention: Manual decompression
Number of subjects: 53
Study 14670288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with 8-, 15-, and 20-day induction protocols
Number of subjects: 53
Study 14670288 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving symptomatic treatments
Number of subjects: 53
Study 10325256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemiluminescent immunoassay (CLIA)
Number of subjects: 505
Study 10325256 — intervention group
Group type: COMPARATOR
Intervention: Radioimmunoassay
Number of subjects: 505
Study 8696906 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5mg/h rt-PA for a maximum of 5 hours
Number of subjects: 288
Study 8696906 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg rt-PA/h for 5 hours (pilot study)
Number of subjects: 288
Study 8696906 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled technique with rt-PA
Number of subjects: 288
Study 2061979 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy administered to 733 patients
Number of subjects: 2231
Study 2061979 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic therapy (1498 patients)
Number of subjects: 2231
Study 6406447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 52
Study 6406447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31062260 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users (n=5987)
Number of subjects: 19114
Study 31062260 — intervention group
Group type: COMPARATOR
Intervention: Non-statin users (n=13127)
Number of subjects: 19114
Study 31062260 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users (unadjusted model)
Number of subjects: 19114
Study 31062260 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users (adjusted model)
Number of subjects: 19114
Study 31062260 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (secondary analysis)
Number of subjects: 19114
Study 31062260 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins in individuals with severe obesity (BMI > 35 kg/m2)
Number of subjects: 19114
Study 31062260 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins in participants aged 75-84 years
Number of subjects: 19114
Study 27273863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure during induction of anesthesia
Number of subjects: 95
Study 27273863 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure during induction of anesthesia
Number of subjects: 95
Study 26475164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 60
Study 26475164 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study 24680228 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate individual cognitive-behavioral therapy for BDD (CBT-BDD), 22 sessions over 24 weeks
Number of subjects: 36
Study 24680228 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate individual cognitive-behavioral therapy for BDD (CBT-BDD)
Number of subjects: 36
Study 24680228 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 36
Study 21626296 — intervention group
Group type: EXPERIMENTAL
Intervention: diet/probiotic
Number of subjects: 125
Study 21626296 — intervention group
Group type: EXPERIMENTAL
Intervention: diet/placebo
Number of subjects: 125
Study 21626296 — intervention group
Group type: COMPARATOR
Intervention: control/placebo
Number of subjects: 125
Study 19324913 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORED guideline for CKD screening in heart attack patients
Number of subjects: 6161
Study 19324913 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORED guideline for CKD screening in stroke patients
Number of subjects: 6161
Study 17313282 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 seconds work / 15 seconds recovery (15/15)
Number of subjects: 12
Study 17313282 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 seconds work / 15 seconds recovery (30/15)
Number of subjects: 12
Study 17313282 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 seconds work / 15 seconds recovery (60/15)
Number of subjects: 12
Study 17313282 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous work (C) at 100% of vVO2max
Number of subjects: 12
Study 15020310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg once daily
Number of subjects: 1702
Study 15020310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 1702
Study 15020310 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 1702
Study 15020310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1702
Study 12856758 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contact with a lesbian person
Number of subjects: 54
Study 12856758 — intervention group
Group type: COMPARATOR
Intervention: No contact with a lesbian
Number of subjects: 54
Study 9657784 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 400